Sustained Release Oral Formulation for Treatment of Parkinson's Disease

• Status: Not yet recruiting
• Trial end date: 2023-08-02
• Target enrollment: 0
• Participant gender: All

Summary

Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson's disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in PD.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota
• Treatments: Carbidopa; Levodopa

Criteria

Inclusion Criteria:

• Diagnosed with idiopathic PD

• Experiencing motor fluctuations

Exclusion Criteria:

• Inability to consent for thmeselves

• Inability to fast